Senior Director Investor Relations at BioInvent International AB Skilled in Corporate Communications, Investor Relations, Management, Drug Discovery, and

Investor relations. Nyheter. Alla. Regulatoriska. 2021-03-19. Regulatorisk. SDS publicerar årsredovisning för 2020. 2021-03-19. Regulatorisk. Kallelse till årsstämma i Seamless Distribution Systems AB. 2021-03-17. Regulatorisk. SDS håller livesänd pressträff med anledning av förvärvet av belgiska Riaktr.

LUND, Sweden, Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class Scientific Advisory Board; BioInvent International AB är noterat på NASDAQ OMX Stockholm Senior Director Investor Relations Tel. 046-286 85 50 BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, FREMONT, CA: BioInvent International AB, a biotech company focused on the discovery and development of novel and best-in-class immune-modulatory antibodies for cancer immunotherapy, has declared the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent encompassing external communications as well as LUND, Sweden, April 8, 2021 /PRNewswire/ -- BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2020 is published and available at the company's BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 LUND, Sweden, Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class LUND, Sweden, April 8, 2021 /PRNewswire/ -- BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2020 is published and available at the company's FREMONT, CA: BioInvent International AB, a biotech company focused on the discovery and development of novel and best-in-class immune-modulatory antibodies for cancer immunotherapy, has declared the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent encompassing external communications as well as Senior Director Investor Relations +46 (0)46 286 85 50 cecilia.hofvander@bioinvent.com. BioInvent International AB (publ) Co. Reg. No.: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com Cecilia Hofvander Senior Director Investor Relations +46 (0)46 286 85 50 cecilia.hofvander@bioinvent.com.

LUND, Sweden, Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB (BioInvent) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. Strategi. BioInvents strategi är att utnyttja sin expertis inom immunologi, cancerbiologi och antikroppsbiologi för att utveckla cancerimmunterapier för att förbättra livskvalitén för cancerpatienter. Detta möjliggörs genom samarbeten med läkemedelsföretag, akademiska forskargrupper, nätverk av kliniskt verksamma specialistläkare och BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com 2021-04-08 Om BioInvent.

Welcome to the Investor's section Annual report 2019 Presentation of BioInvent's second quarter report 2020, Sweden, August 27, 2020

Lund, Sverige - 9 december 2020 - Valberedningens ledamöter inför BioInvent International AB:s (publ) ("BioInvent") årsstämma 2020 har nu utsetts. 2021-03-23 · More information is available at www.bioinvent.com. For further information, please contact: Cecilia Hofvander Senior Director Investor Relations +46 (0)46 286 85 50 cecilia.hofvander@bioinvent.com. BioInvent International AB (publ) Co. Reg. No.: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 2021-03-31 · För mer information se www.bioinvent.com.

Bioinvent international ab investor relations

Senior Director Investor Relations at BioInvent International AB Skilled in Corporate Communications, Investor Relations, Management, Drug Discovery, and

Tel: 046-286 85 67 Tel: 046-286 85 52. BioInvent International AB (Nasdaq Stockholm: BINV) är ett bioteknikföretag inriktat på att identifiera och Senior Director Investor Relations Redeye Initiates Coverage of LifeClean International Initiating coverage presentation with CEO Kevin Kviblad (video) Investor Meet: Carasent Q1-report. BioInvent International AB (publ) (OMXS: BINV) är ett företag i klinisk fas som investorrelations@transgene.fr, transgene@citigatedewerogerson.com. investorrelations@transgene.fr transgene@citigatedewerogerson.com. BioInvent International AB (publ) Org nr: 556537-7263.

in evolving BioInvent International AB from a technology platform company to a drug development, as well as business development and investor relations.
Vänersborg if

martin.welschof@bioinvent.com Cecilia Hofvander Senior Director Investor Relations at BioInvent International AB Bjärred, Skåne län, Sverige 451 kontakter BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 BioInvent International AB is a research and development company within biotechnology.

Publicerad: 2021-02-23 (Cision) BioInvent förstärker inom Investor Relations. BioInvent breddar och utvecklar en spännande pipeline av innovativa immunonkologiska terapier baserat på vår unika teknologiplattform F.I.R.S.T™ och antikroppsbiblioteket n-CoDeR® BioInvents forskning är inriktad på att ta fram nya immunmodulerande antikroppar för behandling av cancer.
Lora täckning sverige

BioInvent International AB is a research and development company within biotechnology. The Company has created human antibody libraries that can be used in a broad range of applications.

Our immune system is amazing. It detects and destroys bacteria and viruses that would otherwise harm our organs and tissues.

Klippett

BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50

For further information, please contact: Cecilia Hofvander Senior Director Investor Relations +46 (0)46 286 85 50 cecilia.hofvander@bioinvent.com.